Overdiagnosis: When Finding Disease Does Not Help

Screening is usually presented as finding disease earlier. It can also find disease that would never have caused a problem, and that possibility grows with age.

What the term actually means

Overdiagnosis is the detection of a genuine abnormality that would never have produced symptoms during the person's lifetime. The finding is real; the harm it would have caused is not.

It is distinct from a false positive, where a test suggests disease that is not present. In overdiagnosis the disease is present and the diagnosis is technically correct.

Because it cannot be identified in any individual case, overdiagnosis is only visible statistically, by comparing screened and unscreened populations over long periods.

Why it happens

Many conditions grow at very different speeds. Some progress quickly, some slowly, and some effectively stop or regress without ever becoming clinically apparent.

Screening is better at finding slow-growing disease simply because slow disease spends longer in a detectable but symptomless state, so tests encounter it more often.

The consequence is a detected population skewed towards the least dangerous forms, which is the opposite of what intuition suggests screening should achieve.

Why age changes the balance

The benefit of finding early disease depends on living long enough for it to have caused harm. That interval shortens as remaining life expectancy shortens.

Competing causes of illness also increase, so a slow-growing abnormality found in a person with several other conditions is less likely to be what determines their future.

Meanwhile the harms of investigation do not shrink. Biopsies, procedures and the physiological stress of treatment are generally tolerated less well with age.

The harms are not only physical

A diagnosis changes how a person sees themselves and how the health system treats them, regardless of whether the underlying condition would ever have mattered.

It can trigger a cascade of surveillance, incidental findings and further tests, each with its own small risk, none of which was part of the original decision.

Insurance, employment and driving arrangements can also change, which are consequences of the label rather than of the disease.

How stopping decisions are approached

Most screening guidance includes an upper age or a life-expectancy condition, precisely because the balance of benefit and harm changes rather than because older people matter less.

The relevant question is usually how long the benefit takes to appear, and whether that interval is shorter than the person's likely remaining years.

That is a discussion to have explicitly with a clinician, since the answer depends on individual health, priorities and the specific test involved.